Compound preparation for lowering blood glucose

Abstract

The invention discloses a compound preparation for lowering blood glucose. The compound preparation, in parts by weight, mainly consists of 20-400 parts of rosiglitazone and 2-40 parts of pioglitazone, and a mixture of the rosiglitazone and the pioglitazone serves as a medicinal ingredient. The compound preparation provided by the invention, in lowering blood glucose, is convenient to take and is safe to use; the compound preparation focuses on improving the sensitivity of a target tissue to insulin, enhancing the capacity of making use of the insulin and improving glycol-metabolism and lipid metabolism, and the compound preparation is capable of effectively lowering fasting blood glucose and postprandial blood glucose. The compound preparation, which fails to lower blood glucose when used independently, is generally used in the combination with other oral hypoglycemic drugs, and is capable of causing a significant synergistic effect; and especially, the compound preparation, applied to patients of type 2 diabetics, is capable of avoiding dependence, and the compound preparation has a remarkable effect on lowering the blood glucose of the patients.

Description

technical field [0001] The invention relates to a compound preparation for lowering blood sugar. Background technique [0002] Diabetes mellitus is a chronic comprehensive disease mainly caused by the disorder of glucose metabolism caused by the absolute or relative deficiency of insulin, or the decreased sensitivity of target cells to insulin. The occurrence of type 2 diabetes is the joint action of peripheral insulin resistance and β-cell dysfunction. the result of. When diabetic patients fail to achieve the goal of blood sugar control after diet and exercise treatment and diabetes health care education, drug treatment is required. [0003] At present, commonly used hypoglycemic drugs are divided into eight types according to the mechanism of action, mainly insulin and its analogs, sulfonylurea secretagogues, metformin, α-glucosidase inhibitors, thiazolidinedione derivatives Sensitizers, phenylanilic acid derivatives secretagogues, GLP-1 receptor agonists, DDP-4 enzyme i...

AI Technical Summary

Problems solved by technology

[0004] However, many hypoglycemic drugs mostly stimulate the human pancreas to secrete insulin, or directly inject insulin into the human body to lower blood sugar, which can easily cause the patient's body to become dependent. The purpose of cure

Images